Notwithstanding promising clinical results, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is facing significant difficulty from managed care entities. Such insurers are https://finniancwrm922453.ivasdesign.com/63189960/company-s-vyndamax-faces-is-meeting-pbm-hurdles-the-copyrightination-of-coverage-battles